1Mitsiades N, Mitsiades C S, Poulaki A V, et al. Bioligic sequelae of nuclear factor-KB blockade in multipla myeloma therapeutic application[J]. Blood, 2002,99( 11 ): 4079-4086.
2Tran J, Rak J ,Sheehan C, et al . Marked induction of the IAP family antiapptotic proteins survivin and XIAP by VEGF in vascular endothelial cells [J]. Biochem Biophys Res Comm,1999,264(3) :781-788.
3Kini A R,Peterson L C,Tallman M S, et al . Angiogenesis in acute promyelocytic leukemia., induction by vascular erdothelial growth factor and inhibition by all-trans retinoic acid[J]. Blood,2001,97(12) :3919-3924.
4Dias S,Shmelkov S V,Lam G, et al . VEGF (165) promotes survival of leukemia cells by Hsp 90 mediated induction of bcl-2 expression and apoptosis inhibition [J]. Blood, 2002,99 ( 7 ) :2532-2540.
5Dias S,Choy M,Alitalo K, et al . Vascular endothelial growth factor ( VEGF )-csignaling through FLT-4 ( VEGFR-3 )mediates leukemia cell proliferation, survival and resistance to chemotheraoy[J]. Blood,2002,99(6) :2179-2184.
6Leppilampi M, Koitinen P. Savolainer E R, et al. The expression of carbonic anhydrase Ⅱ in hematological malignancies[J]. Clin Cancer Res,2002,8(7) :2240-2245.
7Gilliland D G,Griffin J D. The role of FLT3: hematopoiesis and leukemia[J]. Blood,2002,100(5) :1532-1542.
8Buettner R, Mora L B, Jove R. Activated STAT signaling in human tumours provides novel molecular targets for therapeutic intervention[J]. Clin Cancer Res, 2002,8 (4) : 945-954.
9Cohen M H, Williams G, Johnson J R, et al. Approved summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia [ J ]. Clin Cancer Res, 2002, 8(5) : 935-942.
10O'Dwyer M E, Mauro M J, Kurilik G, at al. The impact of clinical evolution on response to imatinib mesylate (STI 571)in accelerated phase CML[J]. Blood,2002,100(5) :1628-1633.
